Merck + Co., Inc.

E Tracy Turner Jones

Yu L Kong

Sheo B Singh

Jerrold M Liesch

Robert T Goegelman

Fernando Pelaez

Robert A Giacobbe

Michael A Goetz

Gregory L Helms

Siobhan Stevens-Miles

Ruth S Sykes

Lucia Herranz

Gerard F Bills

Elvira Munguira

Maria T Diez Matas

Fermentation processes for the production of a compound of the Structural Formula I ##STR1## The compound of Structural Formula I has been shown to have endothelin antagonist activity and is therefore useful in treating cardiovascular disorders, such as hypertension, congestive heart failure, postischemic renal failure vasospasm, cerebral and cardia ischemia, myocardial infarction inflammatory diseases, Raynaud's disease, endotoxin shock and asthma.

Process for the production of a novel endothelin antagonist

There is disclosed a series of macrolides isolated from the fermentation broth of microorganisms identified as MA-6825, MA-6864 and MA-6865. The structure of the novel compounds isolated from the microorganisms is presented based upon analytical studies. The compounds are highly potent antiparasitic, insecticidal, and anthelmintic agents and are related to the class of macrolides known as milbemycins. Compositions for such uses are also disclosed.

Anthelmintic milbemycin analogs of novel microorganisms

Growing community of inventors

Solana Beach, CA, United States of America

E Tracy Turner Jones